Skip to main content

Catheter Precision, Inc. (NYSE-American:VTAK) Expands Sales Team; Expects Corresponding Rise in Revenue Over the Near Term; Anticipates Breakeven by End of Year

FORT MILL, SC / ACCESSWIRE / April 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a leading MedTech company specializing in innovative products for cardiac electrophysiology, including its VIVO and LockeT products, has announced a major expansion in its business development team. The company is bolstering its sales team with experienced industry veterans to drive growth and market penetration.

David Jenkins, Catheter Precision's CEO, commented on the expansion efforts. "This is a group that I have known for almost twenty years. They are top performers from a company which was acquired by a large medical device company a couple years ago. This group led their prior company, with its unique electrophysiology products, to reach over $100 million of sales and then its acquisition for $1.7 billion. I am confident that their efforts will be repeated here at Catheter Precision."

The new expansion of these veteran sales persons includes five hired on and trained in the first quarter, two more slated to start next week, and one more toward the end of April. In addition to these hires, during the first quarter, the company also brought on technical expertise with Madison Spence, most recently from Acutus, and David Pollmeier in Europe, most recently from Galaxy Medical.

"This new group is expected to focus on both product lines, VIVO and LockeT", continued Mr. Jenkins. "Over the last year, we have been primarily working on getting VIVO into key accounts and accumulating clinical data on LockeT. This expansion demonstrates a new effort toward commercialization of both product lines. With a 90% gross margin on both products, we anticipate that the expected increase in revenue will bring about cash flow break even by the end of this calendar year."

Robert Locke, newly hired in the position of Vice President, also commented. "I previously worked with David at EP MedSystems, where we took it from a start up to its acquisition by St. Jude Medical. Those products became well accepted in the market because of the hard-working team put together by David, and those products today are well integrated into the Abbott line of electrophysiology devices. I am excited that we can look forward to the same team effort here at Catheter Precision. I have been on board for just over one month and already I have over ten hospital accounts that either have agreed to order or agreed to try out the new LockeT product. Each of these hospitals performs hundreds of Afib ablations per year. I expect Locket, with its compelling value proposition, to become widely utilized, not just in the US, but worldwide as well, and not just in EP, but in vascular surgery and interventional radiology."

About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.

About LockeT
Catheter Precision's LockeT is a suture retention device intended to assist in hemostasis after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Reincorporated as Ra Medical Systems, Inc. in Delaware in 2018, the Company changed its name to Catheter Precision, Inc. on August 17, 2023.

Cautionary Note Regarding Forward-Looking Statements
This communication contains forward-looking statements. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, the following: our belief that we are well positioned to fortify our sales efforts, our expectation that we can demonstrate the utility and cost effectiveness of our products, our belief regarding the growth and opportunities within our field of cardiac electrophysiology, statements regarding our interpretation of our initial clinical trial data for LockeT and regarding the timing of the completion of our second clinical trial for LockeT, and statements regarding our plans to file and prosecute patents throughout the global marketplace. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption "Risk Factors" in the Company's Form 10-K filed with the SEC and available at These risks and uncertainties include, but aren't limited to, that we do not have sufficient liquidity to fund our operations through May 2024 unless we are able to obtain additional financing or enter into a strategic transaction that would provide additional liquidity, we will not be able to reach profitability unless we are able to achieve our product expansion and growth goals, our research and development and commercialization efforts may depend on entering into agreements with corporate collaborators, we have entered into joint marketing agreements with respect to our products, and may enter into additional joint marketing agreements, that will reduce our revenues from product sales, royalty agreements with respect to our LockeT device will reduce any future profits from this product, if we experience significant disruptions in our information technology systems, our business may be adversely affected, litigation and other legal proceedings may adversely affect our business, if we make acquisitions or divestitures, we could encounter difficulties that harm our business, failure to attract and retain sufficient qualified personnel could also impede our growth, failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock, we have determined that our internal controls and disclosure controls were not effective as of December 31, 2023, and as a result, without effective remediation of the material weaknesses that we have identified, we may not be able to accurately report our financial results or prevent fraud, our revenues may depend on our customers' receipt of adequate reimbursement from private insurers and government sponsored healthcare programs, we may be unable to compete successfully with companies in our highly competitive industry, many of whom have substantially greater resources than we do, our future operating results depend upon our ability to obtain components in sufficient quantities on commercially reasonable terms or according to schedules, prices, quality and volumes that are acceptable to us, and suppliers may fail to deliver components, or we may be unable to manage these components effectively or obtain these components on such terms, if hospitals, physicians and patients do not accept our current and future products or if the market for indications for which any product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any, our medical device operations are subject to pervasive and continuing FDA regulatory requirements, our products may be subject to additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation, and adversely affect our business, changes in trade policies among the U.S. and other countries, in particular the imposition of new or higher tariffs, could place pressure on our average selling prices as our customers seek to offset the impact of increased tariffs on their own products, increased tariffs or the imposition of other barriers to international trade could have a material adverse effect on our revenues and operating results. The risks and uncertainties described above may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, or other pandemics, supply chain disruptions from the Ukraine war or Israeli-Hamas conflict and otherwise, and ongoing volatility in the stock markets and the U.S. economy in general.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

At the Company
David Jenkins

SOURCE: Catheter Precision, Inc

View the original press release on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.